Identification and validation of new breast cancer biomarkers based on integrated metabolomics
Project duration: 01.04.2008 - 31.03.2011 terminated
The Collaborative Project METAcancer has received funding from the European Community's Seventh Framework Programme
(FP7/2007-2013) under grant agreement n° HEALTH-F2-2008-200327.
Breast cancer is the most common cancer in women. In the Western world, approximately one in eight women will develop an invasive breast carcinoma in her lifetime. While the disease is curable in early stages, about 50% of the patients have stage II or III tumors and are potential candidates for systemic therapy. This patient group would benefit from a patient-tailored therapy on the basis of biomarker testing.
While genetic alterations have been extensively characterized in breast cancer, the changes in metabolism that occur downstream from genomic and proteomic alterations have not been analyzed in detail to date.
The metabolome reflects alterations in the pathophysiological state of biological systems. Metabolic alterations can be the consequences of changes in metabolic pathways, but also in signalling pathways, membrane turnover and other cellular networks. Since small changes in enzyme concentrations or activities can lead to large changes in metabolite levels, the metabolome is regarded as the amplified output of a biological system.
The METAcancer objective is to test the hypothesis, that alterations in the level of metabolites can be used for a molecular classification of breast cancer as well as for the identification of new prognostic and predictive biomarkers.
© Images under copyright of METAcancer consortium.